Difference between revisions of "Valrubicin (Valstar)"
Jump to navigation
Jump to search
m |
m |
||
| Line 12: | Line 12: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 9/25/1998: Initial FDA approval for intravesical therapy of [[Bacillus Calmette-Guerin (BCG) | BCG]]-refractory [[Bladder cancer | carcinoma ''in situ'' (CIS) of the urinary bladder]] in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
[[Category:Bladder cancer medications]] | [[Category:Bladder cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1998]] | ||
Revision as of 20:13, 25 October 2014
General information
Class/mechanism: Anthracycline; inhibits the incorporation of nucleosides, interferes with normal activity of DNA topoisomerase II, causing extensive chromosomal damage and cell cycle arrest in G2.[1][2][3]
Route: Intravesicular
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Valrubicin (Valstar) manufacturer's patient drug information - "Understanding Your Therapy With VALSTAR"
- Valrubicin (Valstar) patient drug information (UpToDate)[4]
Diseases for which it is used
History of changes in FDA indication
- 9/25/1998: Initial FDA approval for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.